Over the past decade, regenerative medicine has shifted from conventional cell-based therapies using living stem cells toward cell-free approaches based on their paracrine activity. This transition has opened new opportunities for the treatment of degenerative diseases, inflammatory conditions, and ischemic injuries of the nervous system.
A key component of this approach is exosomes—extracellular vesicles measuring approximately 30–150 nanometers that are naturally released by virtually all cell types and serve as mediators of intercellular communication. According to the latest MISEV2023 guidelines, the scientifically preferred term is small extracellular vesicles (sEVs), reflecting their heterogeneous nature and biological complexity.
Exosomes contain a diverse range of bioactive molecules, including:
Small extracellular vesicles function as natural biological carriers, transporting biologically active cargo that includes:
Exosomes are nanosized biological vesicles that carry molecular signals capable of influencing the behavior of recipient cells. They help redirect damaged cells toward tissue repair, reduce chronic inflammation, and activate the body’s natural regenerative mechanisms.
Exosomes enter target cells through two primary mechanisms: endocytosis and direct membrane fusion.
Endocytosis is an active process by which cells internalize extracellular vesicles.
Several types of endocytosis have been described:
Direct membrane fusion is a passive process in which the lipid bilayer of the exosome fuses directly with the plasma membrane of the target cell, allowing rapid and efficient delivery of its molecular cargo.
The uptake mechanism depends on several factors, including the type of recipient cell, the lipid composition of the exosome membrane, and the intracellular environment of the target cell.
Exosome-based therapy addresses several limitations associated with conventional cell therapy.
Exosomes express minimal levels of major histocompatibility complex (MHC) molecules, reducing the likelihood of immune activation and graft rejection. In addition, they contain immunomodulatory molecules that help regulate the inflammatory response and promote immune homeostasis.
Unlike living cells, exosomes do not contain a nucleus and cannot proliferate or differentiate. As a result, they do not carry the risks associated with uncontrolled cell growth or ectopic tissue formation.
Compared with living cells, exosomes demonstrate excellent stability during storage and transportation. Their lipid membrane protects the biological cargo from enzymatic degradation, while their nanoscale size contributes to the preservation of biological activity.
Exosomes can be stored at −80°C for extended periods without significant loss of activity, facilitating transportation and long-term storage. In contrast, living cells require continuous culture or specialized cryopreservation and may lose viability after thawing.
The blood-brain barrier (BBB) is a highly selective biological barrier that limits the penetration of many therapeutic agents into the central nervous system.
Due to their nanoscale size, exosomes are capable of crossing the blood-brain barrier and delivering therapeutic molecules to brain tissue. This unique property makes them particularly promising for the treatment of neurological disorders, including stroke and other neurodegenerative conditions.
Exosome production is a complex process that consists of two main stages: cell culture and exosome isolation.
Traditional two-dimensional (2D) cell culture systems provide relatively low exosome yields. Therefore, three-dimensional (3D) culture has become the preferred approach for large-scale production.
By growing cells within three-dimensional matrices or spheroids, culture conditions more closely resemble the natural cellular environment, stimulating the release of significantly higher numbers of biologically active extracellular vesicles.
According to Haraszti et al., combining 3D culture with tangential flow filtration (TFF) can increase exosome yield by up to 140-fold compared with conventional production methods.
Traditionally, exosomes have been isolated using sequential ultracentrifugation, which effectively separates extracellular vesicles from most soluble proteins. However, this method is time-consuming, requires specialized equipment, and may affect vesicle morphology.
More recently, tangential flow filtration (TFF) has emerged as an advanced alternative. In this method, the sample flows parallel to the membrane surface rather than directly through it. This approach minimizes membrane fouling, enables continuous processing, improves filtration efficiency, and allows simultaneous concentration and purification of the product under sterile conditions.
To ensure the identity, purity, and quality of isolated exosomes, each production batch undergoes analytical validation using electron microscopy and Western blot analysis.
Electron microscopy is used to evaluate vesicle morphology, confirm their characteristic cup-shaped or spherical lipid bilayer structure, and assess samples for the presence of contaminants or structural abnormalities.
Western blot analysis is an immunoassay used to detect specific proteins based on antigen-antibody interactions. It confirms the presence of characteristic exosomal markers—including CD63, CD81, and CD9—thereby verifying that the isolated vesicles exhibit characteristic exosomal markers.
Exosome-based therapies are being actively investigated across a wide range of medical specialties.
| Clinical Application | Route of Administration | Clinical Development Status (2026) |
|---|---|---|
| Spinal cord injury | Intrathecal | Phase II–III |
| Acute ischemic and hemorrhagic stroke | Intravenous infusion | Phase II |
| Hip and knee osteoarthritis | Intra-articular injection | Phase II–III; commercial products available in some markets |
| Atopic, contact, and systemic dermatitis | Topical application / intradermal injection | Phase II; commercial cosmetic products available |
| COVID-19 | Intravenous infusion | Phase II |
Neurological rehabilitation is considered one of the most promising areas for exosome-based therapy. Exosomes derived from neural stem cells (NSCs) and mesenchymal stem cells (MSCs) have demonstrated the ability to cross the blood-brain barrier and influence key mechanisms involved in neuroplasticity.
In spinal cord injury, bone marrow-derived MSC (BM-MSC) exosomes have shown the potential to improve locomotor recovery. In ischemic stroke, administration of neural stem cell-derived exosomes within the first week after symptom onset has been associated with enhanced neurogenesis in the subventricular zone, reduced neuronal apoptosis in the peri-infarct region, and improved motor function over a six-month period.
Preliminary studies also suggest the potential of exosome therapy in neurodegenerative diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).
Dermatology is one of the fastest-growing areas of exosome research and clinical application.
Exosomes derived from fibroblasts and keratinocytes stimulate collagen synthesis, improve skin elasticity, and accelerate tissue repair following dermatological procedures.
In patients with atopic dermatitis, topical application of exosome-containing formulations for four weeks has been associated with reduced itching and lower SCORAD scores.
For post-acne scars, combined treatment with microneedling and exosome therapy has demonstrated greater improvements in scar depth and skin texture compared with microneedling alone.
Exosome therapy is also being investigated as a regenerative approach for skin aging. Repeated intradermal administration over several months has been associated with improved skin elasticity, enhanced radiance, and a reduction in wrinkle depth.
MSC-derived exosomes exhibit immunomodulatory properties by promoting the activity of FoxP3⁺ regulatory T cells (Tregs) and increasing the production of anti-inflammatory mediators such as IL-10 and TGF-β.
Clinical studies are currently evaluating exosome therapy in conditions including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and severe COVID-19 associated with hyperinflammation.
Early findings suggest that exosome therapy may contribute to improved joint function, modulation of inflammatory responses, and restoration of immune homeostasis.
Exosome-based therapy represents one of the most rapidly advancing fields within regenerative medicine. By harnessing the biological activity of extracellular vesicles rather than living cells, this approach combines regenerative potential with a favorable safety profile and simplified manufacturing and storage.
Although many applications remain under clinical investigation, growing scientific evidence supports the potential of MSC-derived exosomes across multiple therapeutic areas, including neurology, orthopedics, dermatology, and immune-mediated diseases. Continued advances in manufacturing, quality control, and clinical research are expected to further expand their role in the future of regenerative medicine.
Closing this window, you agree that you have read the information below.
SELF-MEDICATION CAN BE HARMFUL TO YOUR HEALTH!
